Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Sponsor
Dong-A University
Study ID
NCT05225077
Phase
PHASE4
Status
Unknown

Conditions

  • Cardiac Catheterization
  • Percutaneous Coronary Intervention
  • Renal Insufficiency, Chronic

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

Study Details

This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Key Dates

Start date
Jan 1, 2022
Status verified
Jan 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2023

Study Design

Enrollment
600 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Dapagliflozin 10mg group
    Dapagliflozin 10 mg once a day for 1 month after the procedure.
  • No Intervention: Non-intervention group
    No intervention.

Primary Outcome Measure

Incidence of contrast induced nephropathy [ Time Frame: 48 hours ]

Related Studies